Valuation : Curis, Inc.

Market Cap 3.11M 2.68M 2.52M 2.3M 4.33M 298M 4.34M 29.85M 11.65M 150M 11.69M 11.44M 498M P/E 2026 *
-0.06x
P/E 2027 * -0.21x
Enterprise Value 3.11M 2.68M 2.52M 2.3M 4.33M 298M 4.34M 29.85M 11.65M 150M 11.69M 11.44M 498M EV / Sales 2026 *
-
EV / Sales 2027 * 0.34x
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Curis, Inc.

1 day-0.67%
1 week-5.70%
Current month-70.32%
1 month-70.08%
3 months-86.86%
6 months-93.46%
Current year-92.45%
1 week 1.4
Extreme 1.4
1.65
1 month 1.4
Extreme 1.4
5.5
Current year 1.4
Extreme 1.4
24.2
1 year 1.4
Extreme 1.4
39
3 years 1.4
Extreme 1.4
349.8
5 years 1.4
Extreme 1.4
3,616
10 years 1.4
Extreme 1.4
7,440
Manager TitleAgeSince
Chief Executive Officer 59 24/09/2018
Director of Finance/CFO 54 05/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 01/11/2003
Chairman 84 16/05/2017
Director/Board Member 71 03/06/2010
Date Insider Type Main position Quantity % Market Cap.
7/7/26 A Free

Chief Executive Officer

110,090 0.2824%
7/7/26 A Free

Director

6,800 0.0174%
7/7/26 A Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%-5.70%-95.54%-99.37% 3.11M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.45%-1.64%+60.87%+87.70% 27.46B
Weighted average by Cap. -1.70%-1.06%+96.28%+129.03%

Financials

2026 *2027 *
Net sales - 9.25M 7.97M 7.47M 6.82M 12.85M 884M 12.89M 88.67M 34.59M 446M 34.73M 33.97M 1.48B
Net income -52.02M -44.82M -42.03M -38.36M -72.27M -4.97B -72.5M -499M -195M -2.51B -195M -191M -8.32B -45.23M -38.98M -36.54M -33.36M -62.84M -4.32B -63.04M -434M -169M -2.18B -170M -166M -7.24B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
28/08/26 $1.490 -0.67% 119,833
27/08/26 $1.500 -2.60% 288,289
26/08/26 $1.540 -3.14% 105,410
25/08/26 $1.590 +0.63% 142,438
24/08/26 $1.580 0.00% 83,105
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.490USD
Average target price
42.67USD
Spread / Average Target
+2,763.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRIS Stock